Arcutis Biotherapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Arcutis Biotherapeutics generated cash of -$247,057,000, which is more than the previous year. Cash used in financing activities reached the amount of $101,323,000 last year. Net change in cash is therefore $34,448,000.
Cash Flow
| 2017 | -3.77M | 0 | 7.11M |
|---|---|---|---|
| 2018 | -14.08M | -11.53M | 61.59M |
| 2019 | -42.83M | -26.32M | 93.10M |
| 2020 | -113.03M | -181.82M | 298.14M |
| 2021 | -174.62M | -75.95M | 281.94M |
| 2022 | -257.71M | -87.19M | 301.79M |
| 2023 | -247.05M | 180.23M | 101.32M |
ARQT Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 54.87M | 97.99M | 66.62M | 63.33M | 39.39M | 3.41M | 74K |
Operating activities | |||||||
Net income | -262.14M | -311.45M | -206.35M | -135.67M | -41.99M | -19.25M | -4.97M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 1.52M | 934K | 454K | 122K | 195K | 0 | 0 |
Stock-based compensation expense | 38.81M | 32.68M | 23.89M | 7.94M | 824K | 0 | 27K |
| Deferred income tax benefit | 38.81M | 32.68M | 23.89M | 7.94M | 824K | 0 | 27K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | -17.34M | -8.45M | 0 | 0 | 0 | 0 | 0 |
Inventories | -5.62M | -7.51M | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 3.15M | 1.56M | 245K | 5.67M | -458K | 1.26M | 537K |
Cash generated by operating activities | -247.05M | -257.71M | -174.62M | -113.03M | -42.83M | -14.08M | -3.77M |
Investing activities | |||||||
Purchases Of Investments | -225.84M | -415.38M | -292.50M | -279.10M | -60.83M | -11.53M | 0 |
Investments In Property Plant And Equipment | -428K | -23.28M | -995K | -321K | -295K | 0 | 0 |
Acquisitions Net | 0 | 22.95M | 74.95M | 181.50M | 26.03M | 0 | 0 |
Cash generated by investing activities | 180.23M | -87.19M | -75.95M | -181.82M | -26.32M | -11.53M | 0 |
Financing activities | |||||||
Common Stock Issued | 98.90M | 176.04M | 209.59M | 298.14M | 94.23M | 0 | 7.06M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 125M | -72.35M | 0 | 0 | 0 | 50K |
Cash used in financing activities | 101.32M | 301.79M | 281.94M | 298.14M | 93.10M | 61.59M | 7.11M |
Net Change In Cash | 34.44M | -43.11M | 31.36M | 3.28M | 23.94M | 35.97M | 3.34M |
Cash at end of period | 89.32M | 54.87M | 97.99M | 66.62M | 63.33M | 39.39M | 3.41M |
| Data source | Data source | Data source | Data source | Data source |